Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels

F. Angelucci, G. Spalletta, F. Di Iulio, A. Ciaramella, F. Salani, A. E. Varsi, W. Gianni, G. Sancesario, C. Caltagirone, P. Bossù

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline with loss of memory. In the last years there has been a great interest on the early phases of AD, trying to identify the pathogenic mechanisms of AD and define early treatment modalities. In particular, Mild Cognitive Impairment (MCI) is attractive because it represents a transitional state between normal aging and dementia, although not all MCI patients automatically convert to AD. The neurotrophin brain-derived neurotrophic factor (BDNF) is critical for survival and function of neurons that degenerate in AD and represents a potential neuroprotective agent. However, opposite data on serum levels of BDNF have been reported in AD patients, probably reflecting differences in patient recruitment and stage of the disease. Thus, in this study we measured BDNF serum levels in AD patients (with different degree of severity), MCI patients and healthy subjects. We found that serum BNDF levels were significantly increased in MCI and AD patients when compared to healthy subjects and this increase in AD patients was neither dependent on illness severity, nor on treatment with Acetylcholinesterase inhibitors and/or antidepressant medications. Our findings indicate that BDNF serum levels increase in MCI and AD patients, supporting the hypothesis of an upregulation of BDNF in both preclinical phase of dementia (MCI) and clinical stages of AD. Other studies are necessary to establish a direct link between BDNF peripheral levels and AD longitudinal course, as well as the role of other factors, such as blood cell activation, in determining these events.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalCurrent Alzheimer Research
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Brain-Derived Neurotrophic Factor
Alzheimer Disease
Serum
Dementia
Cognitive Dysfunction
Healthy Volunteers
Cholinesterase Inhibitors
Memory Disorders
Nerve Growth Factors
Neuroprotective Agents
Neurodegenerative Diseases
Patient Selection
Antidepressive Agents
Blood Cells
Up-Regulation

Keywords

  • Acetylcholinesterase inhibitors
  • Alzheimer
  • Antidepressant drugs
  • BDNF
  • MCI
  • Neurodegeneration
  • Neuroprotection
  • Serum levels

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels. / Angelucci, F.; Spalletta, G.; Di Iulio, F.; Ciaramella, A.; Salani, F.; Varsi, A. E.; Gianni, W.; Sancesario, G.; Caltagirone, C.; Bossù, P.

In: Current Alzheimer Research, Vol. 7, No. 1, 01.2010, p. 15-20.

Research output: Contribution to journalArticle

@article{0b64d94e01e847b6835c5f1c0012a8ee,
title = "Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels",
abstract = "Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline with loss of memory. In the last years there has been a great interest on the early phases of AD, trying to identify the pathogenic mechanisms of AD and define early treatment modalities. In particular, Mild Cognitive Impairment (MCI) is attractive because it represents a transitional state between normal aging and dementia, although not all MCI patients automatically convert to AD. The neurotrophin brain-derived neurotrophic factor (BDNF) is critical for survival and function of neurons that degenerate in AD and represents a potential neuroprotective agent. However, opposite data on serum levels of BDNF have been reported in AD patients, probably reflecting differences in patient recruitment and stage of the disease. Thus, in this study we measured BDNF serum levels in AD patients (with different degree of severity), MCI patients and healthy subjects. We found that serum BNDF levels were significantly increased in MCI and AD patients when compared to healthy subjects and this increase in AD patients was neither dependent on illness severity, nor on treatment with Acetylcholinesterase inhibitors and/or antidepressant medications. Our findings indicate that BDNF serum levels increase in MCI and AD patients, supporting the hypothesis of an upregulation of BDNF in both preclinical phase of dementia (MCI) and clinical stages of AD. Other studies are necessary to establish a direct link between BDNF peripheral levels and AD longitudinal course, as well as the role of other factors, such as blood cell activation, in determining these events.",
keywords = "Acetylcholinesterase inhibitors, Alzheimer, Antidepressant drugs, BDNF, MCI, Neurodegeneration, Neuroprotection, Serum levels",
author = "F. Angelucci and G. Spalletta and {Di Iulio}, F. and A. Ciaramella and F. Salani and Varsi, {A. E.} and W. Gianni and G. Sancesario and C. Caltagirone and P. Boss{\`u}",
year = "2010",
month = "1",
doi = "10.2174/156720510790274473",
language = "English",
volume = "7",
pages = "15--20",
journal = "Current Alzheimer Research",
issn = "1567-2050",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels

AU - Angelucci, F.

AU - Spalletta, G.

AU - Di Iulio, F.

AU - Ciaramella, A.

AU - Salani, F.

AU - Varsi, A. E.

AU - Gianni, W.

AU - Sancesario, G.

AU - Caltagirone, C.

AU - Bossù, P.

PY - 2010/1

Y1 - 2010/1

N2 - Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline with loss of memory. In the last years there has been a great interest on the early phases of AD, trying to identify the pathogenic mechanisms of AD and define early treatment modalities. In particular, Mild Cognitive Impairment (MCI) is attractive because it represents a transitional state between normal aging and dementia, although not all MCI patients automatically convert to AD. The neurotrophin brain-derived neurotrophic factor (BDNF) is critical for survival and function of neurons that degenerate in AD and represents a potential neuroprotective agent. However, opposite data on serum levels of BDNF have been reported in AD patients, probably reflecting differences in patient recruitment and stage of the disease. Thus, in this study we measured BDNF serum levels in AD patients (with different degree of severity), MCI patients and healthy subjects. We found that serum BNDF levels were significantly increased in MCI and AD patients when compared to healthy subjects and this increase in AD patients was neither dependent on illness severity, nor on treatment with Acetylcholinesterase inhibitors and/or antidepressant medications. Our findings indicate that BDNF serum levels increase in MCI and AD patients, supporting the hypothesis of an upregulation of BDNF in both preclinical phase of dementia (MCI) and clinical stages of AD. Other studies are necessary to establish a direct link between BDNF peripheral levels and AD longitudinal course, as well as the role of other factors, such as blood cell activation, in determining these events.

AB - Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline with loss of memory. In the last years there has been a great interest on the early phases of AD, trying to identify the pathogenic mechanisms of AD and define early treatment modalities. In particular, Mild Cognitive Impairment (MCI) is attractive because it represents a transitional state between normal aging and dementia, although not all MCI patients automatically convert to AD. The neurotrophin brain-derived neurotrophic factor (BDNF) is critical for survival and function of neurons that degenerate in AD and represents a potential neuroprotective agent. However, opposite data on serum levels of BDNF have been reported in AD patients, probably reflecting differences in patient recruitment and stage of the disease. Thus, in this study we measured BDNF serum levels in AD patients (with different degree of severity), MCI patients and healthy subjects. We found that serum BNDF levels were significantly increased in MCI and AD patients when compared to healthy subjects and this increase in AD patients was neither dependent on illness severity, nor on treatment with Acetylcholinesterase inhibitors and/or antidepressant medications. Our findings indicate that BDNF serum levels increase in MCI and AD patients, supporting the hypothesis of an upregulation of BDNF in both preclinical phase of dementia (MCI) and clinical stages of AD. Other studies are necessary to establish a direct link between BDNF peripheral levels and AD longitudinal course, as well as the role of other factors, such as blood cell activation, in determining these events.

KW - Acetylcholinesterase inhibitors

KW - Alzheimer

KW - Antidepressant drugs

KW - BDNF

KW - MCI

KW - Neurodegeneration

KW - Neuroprotection

KW - Serum levels

UR - http://www.scopus.com/inward/record.url?scp=77949755052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949755052&partnerID=8YFLogxK

U2 - 10.2174/156720510790274473

DO - 10.2174/156720510790274473

M3 - Article

C2 - 20205668

AN - SCOPUS:77949755052

VL - 7

SP - 15

EP - 20

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 1

ER -